Medexus Pharmaceuticals Inc.
TSX:MDP.TO · Toronto Stock Exchange
+$0.05 today
Vol 0.02M · Avg 0.05M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $2.2M +1150.0% | -$214.0K -117.5% | $1.2M +142.4% | -$2.9M +89.8% | -$28.3M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $7.2M +23.6% | $5.8M -4.5% | $6.1M -1.0% | $6.1M +2.8% | $6.0M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$807.0K -352.2% | $320.0K +105.1% | -$6.3M -565.5% | -$941.0K +70.9% | -$3.2M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $411.0K -12.4% | $469.0K -61.4% | $1.2M -35.4% | $1.9M +48.3% | $1.3M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $5.8M +193.8% | -$6.2M +59.2% | -$15.3M -357.3% | $5.9M +2364.9% | $240.6K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $10.5M +730.3% | -$1.7M +79.7% | -$8.2M -248.7% | $5.5M +219.5% | -$4.6M | $592.6M | $1.3B | $626.2M |
| Inventory | -$4.6M +31.7% | -$6.7M -239.0% | -$2.0M +76.2% | -$8.4M -70086.6% | -$11.9K | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $0 | $0 +100.0% | -$5.0M -211.5% | $4.5M -26.1% | $6.1M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$97.0K -104.4% | $2.2M +218149.2% | $1.0K -100.0% | $4.2M +441.5% | -$1.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $9.2M -50.6% | $18.6M +60.5% | $11.6M +202.1% | -$11.3M -139.0% | $29.1M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $24.0M +28.4% | $18.7M +1396.0% | -$1.4M -22.4% | -$1.2M -123.4% | $5.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$2.7M -924.8% | -$266.0K +26.5% | -$362.0K +95.3% | -$7.7M +28.3% | -$10.8M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$3.3M -2.0% | -$3.2M -78.6% | -$1.8M -197.5% | -$604.4K +36.5% | -$952.0K | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$2.5M -1077.3% | -$216.0K -256.3% | $138.2K +101.8% | -$7.5M -249921.1% | $3.0K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$6.0M -72.5% | -$3.5M -102.1% | -$1.7M +79.0% | -$8.2M +30.0% | -$11.7M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$14.2M +46.1% | -$26.4M -346.0% | $10.7M +187.8% | $3.7M +19726.3% | -$19.0K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $19.2M +151.9% | $7.6M | $0 | $0 -100.0% | $22.6M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$4.1M +40.2% | -$6.9M -59.5% | -$4.3M -41.2% | -$3.1M +22.0% | -$3.9M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $796.0K +103.5% | -$23.0M -459.8% | $6.4M +866.1% | $663.0K -96.5% | $18.7M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$111.0K -5450.0% | -$2.0K +98.9% | -$189.0K -800.0% | $27.0K -98.1% | $1.5M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $18.7M +339.5% | -$7.8M -356.1% | $3.1M +135.1% | -$8.7M -164.5% | $13.5M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $21.3M +15.5% | $18.4M +1121.5% | -$1.8M +79.7% | -$8.9M -55.6% | -$5.7M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
iAnthus Capital Holdings, Inc.
IAN.CN
$69.73M
Decibel Cannabis Company Inc.
DB.V
$69.23M
Vext Science, Inc.
VEXT.CN
$61.92M
Planet 13 Holdings Inc.
PLTH.CN
$60.79M
BioNxt Solutions Inc.
BNXT.CN
$48.08M
C21 Investments Inc.
CXXI.CN
$43.91M
MariMed Inc.
MRMD.CN
$37.93M
The Cannabist Company Holdings Inc.
CBST.NE
$17.47M
InnoCan Pharma Corporation
INNO.CN
$14.17M
SEC Filings
Recent regulatory filings
No filings found.
Does MDP.TO generate free cash flow?
Medexus Pharmaceuticals Inc. (MDP.TO) generated $21.31M of free cash flow in fiscal 2025.
How much operating cash flow does MDP.TO produce?
Operating cash flow was $24.03M, before capital expenditures of $2.73M.
Explore More
Continue the stock analysis
Jump to another research area for this company.